We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
A clinical research team’s goal is to support the implementation, conduct, and monitoring of research studies and corresponding protocols. There is a need to ensure that study teams have adequate resources and regulatory support to successfully adhere to regulations and good clinical research practices. Our team, the UC Davis Division of Infectious Diseases Research Unit (IDRU), sought to establish a One Signature Initiative program for all studies and protocols supported by the IDRU. The One Signature Initiative designates one point of contact from each ancillary team or department to sign delegation and training logs, who in turn is delegated to train their team. The goals of the One Signature Initiative were, and are still, to reduce task redundancy, lessen regulatory burden on research teams, and minimize audit findings. Since the implementation of the One Signature Initiative in 2023, acceptance has been favorable, and we have expanded its footprint by incorporating it into our standard operating procedures. This article discusses our experiences, and ancillary departments’ experiences, with the One Signature Initiative. Our experience is an example of how a One Signature Initiative can be developed that is efficient, effective, and well-accepted by clinical research stakeholders.
Evaluating the algorithmic behavior of interactive systems is complex and time-consuming. Developers increasingly recognize the importance of accountability for their algorithmic creations’ unanticipated behavior and resulting implications. To mitigate this phenomenon, developers not only need to concentrate on the observable inaccuracies that can be measured quantitatively but also the more subjective outcomes that can perpetuate social bias, which are challenging to identify. We require a new approach that involves humans in scrutinizing algorithmic behavior. It leverages a combination of quantitative and qualitative methods to support an ethical, value-aligned design and a system’s lifecycle, informed by users’ perception and values. To date, the literature lacks an agreed-upon framework for such an approach. Consequently, we propose an oversight framework, Modular Oversight Methodology (MOM), which aids developers in assessing the behavior of their systems by involving a carefully crowdsourced society-in-the-loop. The framework facilitates the development and execution of an oversight process and can be tweaked according to the domain and application of use. Through such an oversight process, developers can assess the human perception of the algorithmic behavior under inspection, and extract valuable insights that will aid in assessing its implications. We present the MOM framework, as a first step toward tailoring more robust, domain-specific solutions to exercise human oversight over algorithms, as a means for software developers to keep the generated output of their solutions fair and trustworthy.
Health technology assessment (HTA) programs inform decision making about the value and reimbursement of new and existing health technologies; however, they are under increasing pressure to demonstrate that they are a cost-effective use of finite healthcare resources themselves. The 2023 HTAi Global Policy Forum (GPF) discussed the value and impact of HTA, including how it is assessed and communicated, and how it could be enhanced in the future. This article summarizes the discussions held at the 2023 HTAi GPF, where the challenges and opportunities related to the value and impact of HTA were debated. Core themes and recommendations identified that defining the purpose of value and impact assessment is an essential first step prior to undertaking it, and that it can be done through the use and expansion of existing tools. Further work around aligning HTA programs with underlying societal values is needed to ensure the long-term value and impact of HTA. HTA could also have a role in assessing the efficiency of the wider health system by applying HTA methods or concepts to broader budgetary allocations and organizational aspects of health care. Stakeholders (particularly patients, industry, and clinicians but also payers, wider society, and the media) should ideally be actively engaged when undertaking the value and impact assessment of HTA. More concerted efforts in communicating the role and remit of HTA bodies would also help stakeholders to better understand the value and impact of HTA, which in turn could improve the implementation of HTA recommendations and application to future actions in the lifecycle of technologies.
The performance of the embryology laboratory is of imperative importance for the successful outcome of an assisted reproductive technology (ART) cycle. The development and viability of gametes and embryos can be compromised by small fluctuations in their environment, so it is crucial to establish optimal culture conditions at which gametes and embryos are attained and maintained. Having a robust control of culture conditions means that it is not necessary to search for a needle in a haystack when trouble-shooting. In order to ensure and maintain these very specific conditions, quality control (QC) routines need to be established with quality specifications for each quality parameter. These parameters are assessed on a daily, weekly, monthly or annual basis to determine whether they meet certain specifications, followed by any necessary fine-tuning to bring the levels back within the acceptable limits of uncertainty of measurement.
The SUERC Radiocarbon Laboratory reports approximately 3000 unknown samples per year with an additional 1200 samples processed for quality assurance purposes. In addition to the primary OxII standard (SRM-4990C) required for AMS batch normalization, secondary “known-age” standards have been used over many years to evaluate individual batch quality. These have included wood (as prepared alpha-cellulose), barley mash, humic acid, a background mammoth bone, known-age bones, and a whisky sample. In this paper, we present some of the results gathered over routine laboratory operation (for more than 10 years) and examine the results illustrating how they are being used to monitor and quality assure performance. Since many of these samples have also been used in the Glasgow intercomparisons, we will also reflect on the results, as well as the actual and potential uses of such samples.
It is not enough to study animal welfare; our responsibility is to promote it. To this end, we need to step out of our laboratories and develop robust protocols for assessing welfare in groups of animals on farms or in the laboratory. While these protocols must incorporate principles derived from detailed scientific study they will, in practice, need to be based on clinical observations and records that an assessor can acquire at a single visit. Such assessments must also be comprehensive: approaches based only on behaviour, or motivational state, or physical appearance, or performance records, can never tell the full story. The ‘Five Freedoms’ provide a comprehensive template that incorporates the different elements that define welfare state. However they only describe welfare at the time of observation. Protocols, for example, for on-farm assessment need to include measurements and records that provide evidence of long-term consequences of the quality of husbandry practices (eg body condition, chronic injuries). This paper reviews approaches developed at Bristol for the on-farm evaluation of welfare in dairy cows and free-range hens. The criteria used to assess welfare from clinical evidence were developed through expert consultation using the ‘Delphi’ review process. Experts were also asked to make value judgements as to the seriousness of different elements of poor welfare by indicating the point at which intervention would be necessary to resolve specific problems. This study identified a serious limitation of Quality Assurance schemes that seek to encompass many different elements of welfare into a single index that ranks overall welfare as acceptable or unacceptable. Specific farms had specific welfare problems and these required specific solutions.
This paper briefly reviews the development of monitoring procedures used for the assessment of husbandry and welfare within Farm Quality Assurance (QA) schemes. Most current protocols are based on measures of the resources, records and management provisions necessary to promote good husbandry. However, it is now generally accepted that monitoring protocols should be largely or wholly made up of direct, animal-based measurements of animal welfare. Whether based on provisions or outcomes, many current schemes lack impact, partly because they do not necessarily lead to effective action on-farm and partly through lack of public awareness or trust in the claimed benefits of the scheme. This paper proposes the concept of the ‘Virtuous Bicycle’ as a delivery vehicle for improvements in farm animal welfare through simultaneous operation of two virtuous cycles, one on-farm, involving assessment, action and review, the other at the retailer level, involving assurance and promotion, based on proof of compliance.
The objective of the present retrospective analysis was to review between- and within-sector variations in an outcome-based measure of animal welfare throughout slaughterhouses that currently supply to Tesco Stores Ltd, UK. Non-conformances in relation to individual scheme standards were designated a specific level in terms of severity and frequency and from this a single outcome status, based on a ‘traffic-light’ system is assigned to the site (which informs both subsequent corrective action and future inspection frequency). Sector-specific, country and time differences were found and underlying contributory factors and associated commercial implications are reviewed.
This paper describes the implementation and simultaneous promotion of an action plan designed to ensure animal welfare standards on-farm that exceed the requirements for acceptability in law. The approach is based on two action cycles, the producer and retailer cycles, The producer cycle, involving welfare audit and the implementation of an action plan for welfare has four stages: self-assessment; independent audit; creation of an action plan based on identification of principal hazards and critical control points; review; and revision of the action plan depending upon assessment of outcomes. The retailer cycle is designed to set quality standards for animal welfare, demonstrate compliance, promote proven high welfare products and reward producers. The paper reviews some incentives and constraints to action for both farmers and retailers and presents encouraging examples of the extent to which both producers and retailers have responded to increased public demand for high welfare products.
This chapter discusses the concept, design, implementation challenges and emerging models of successful strategic purchasing (SP) in low- and middle-income countries (L&MICs). The purchasing function is concerned with allocation and use of funds to ensure more value for the existing money by setting the right financial incentives to providers and ensuring that all individuals have access to needed health services. There is a marked difference across countries in terms of how they purchase health care. Passive purchasing implies following a predetermined budget or simply paying bills when presented. In contrast, SP involves a continuous search for the best ways to maximize health system performance by proactively answering questions such as – for whom to buy, what to buy, from whom to buy, how to pay and what impact. There are enablers and choke points for implementation of provider payment systems that need consideration. For L&MICs to do SP effectively, calls for building technical capacity in provider payment, greater policy coherence, institutional relationship between government and purchasers, and a step-by-step approach allowing countries to move towards SP.
Head and neck (HN) radiotherapy (RT) is complex, involving multiple target and organ at risk (OAR) structures delineated by the radiation oncologist. Site-agnostic peer review after RT plan completion is often inadequate for thorough review of these structures. In-depth review of RT contours is critical to maintain high-quality RT and optimal patient outcomes.
Materials and Methods:
In August 2020, the HN RT Quality Assurance Conference, a weekly teleconference that included at least one radiation oncology HN specialist, was activated at our institution. Targets and OARs were reviewed in detail prior to RT plan creation. A parallel implementation study recorded patient factors and outcomes of these reviews. A major change was any modification to the high-dose planning target volume (PTV) or the prescription dose/fractionation; a minor change was modification to the intermediate-dose PTV, low-dose PTV, or any OAR. We analysed the results of consecutive RT contour review in the first 20 months since its initiation.
Results:
A total of 208 patients treated by 8 providers were reviewed: 86·5% from the primary tertiary care hospital and 13·5% from regional practices. A major change was recommended in 14·4% and implemented in 25 of 30 cases (83·3%). A minor change was recommended in 17·3% and implemented in 32 of 36 cases (88·9%). A survey of participants found that all (n = 11) strongly agreed or agreed that the conference was useful.
Conclusion:
Dedicated review of RT targets/OARs with a HN subspecialist is associated with substantial rates of suggested and implemented modifications to the contours.
In the last chapter, we discussed the first method (RFLP) used in DNA typing. This procedure targeted relatively long DNA fragments (VNTRs) containing many repeated units of a base pair sequence. We ended by noting that they were not amenable to automation and therefore not destined for widespread forensic applications. However, by the early 1990s, many factors coalesced to set the stage for a leap in DNA typing capabilities. For example, the forensic and legal community had adjusted to DNA evidence, and analysts had moved from serological techniques such as ABO to genetic typing utilizing multiple DNA markers. Additionally, researchers in molecular biology, including in genomic sequencing, had identified many shorter repeat sequences that exhibited variation among individuals in a population.
To evaluate the dosimetric effect of modelling a non-homogeneous couch on patients’ quality assurance (QA) gamma pass rates for intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) techniques.
Materials and Methods:
A non-homogeneous treatment couch (TxT 550 TTM, CIVCO, USA) was imaged using the LINAC mounted cone-beam computer tomography (CBCT) system. Modelling this couch in different situations, including incomplete (homogeneous model), correct model and not defined situations in the treatment planning system (TPS), was performed based on the geometrical and material densities data extracted from the CBCT images. Calculated gamma pass rates between TPS dose calculations and the measurements in a phantom for different couch models were obtained and compared at two gamma criteria (2%-2 mm and 3%-3 mm).
Results:
Comparing TPS calculations for the correct modelled couch and the measurements showed high gamma pass rates for both the IMRT and VMAT techniques (96·5 ± 0·9%, 99·2 ± 0·5% for IMRT in 2%-2 mm and 3%-3 mm criteria; 97·5 ± 0·8%, 99·4 ± 0·5% for VMAT). The overall gamma pass rate of the IMRT plan QAs was reduced by about 2% and 3% on average for incomplete and no couch modelling, respectively. These reductions for VMAT techniques were 2·5% and 4·3%, respectively.
Conclusions:
Non-homogeneous couches have different parts with different attenuations, which can be correctly defined using LINAC CBCT. Modelling of treatment couch has a significant effect on patient QA results for VMAT and IMRT plans, especially in radiation fields/subfield transmitting from the couch. We suggest using LINAC CBCTs as an appropriate device for couch modelling in modulated radiotherapy techniques.
Intensity-modulated radiation therapy (IMRT) treatment delivery requires pre-treatment patient-specific quality assurance (QA) for the dosimetry verification due to its complex multileaf-collimator movement. The prostate target close position between the bladder and rectum requires a tight margin during planning, and mistreatment would have a huge impact on the patient. A commercially available QA tool consists of a homogeneous medium and does not represent an exact photon interaction on the tumour and also on the nearby healthy organ.
Objective:
A heterogeneous male pelvis phantom was developed and investigated the efficiency of the treatment planning system (TPS) calculation on the off-axis region.
Methods:
Polymethyl methacrylate was used for the phantom housing, and the material closed to the bladder, rectum and prostate density was chosen to construct the organ models. The phantom was scanned and validated by the computed tomography number and density. An IMRT treatment was planned in the Monaco TPS, and a thermoluminescent dosimeter (TLD-100) was used to validate the point dosimetry. In addition, an EGSnrc Monte Carlo simulation was carried out to validate the phantom dosimetry.
Results & Discussion:
The dose measurement between TLD-100, TPS, and EGSnrc was compared and validated in the pelvis phantom. In the prostate region, the dose difference was within ± 5%, and the maximum dose difference outside-the-irradiated field was up to 20·07 % and 47·31 % in TPS and TLD-100, respectively. Meanwhile, the measured dose was lower than the calculated dose, and it was apparent for the dose outside-the-irradiated field.
Conclusion:
The developed heterogeneity male pelvis phantom was validated and verified to be an important QA device for validating radiation dosimetry in the pelvis region. The dose outside-the-irradiated field was underestimated by both TPS and TLD, respectively.
Peer review is an essential quality assurance component of radiation therapy planning. A growing body of literature has demonstrated substantial rates of suggested plan changes resulting from peer review. There remains a paucity of data on the impact of peer review rounds for stereotactic body radiation therapy (SBRT). We therefore aim to evaluate the outcomes of peer review in this specific patient cohort.
Methods and materials:
We conducted a retrospective review of all SBRT cases that underwent peer review from July 2015 to June 2018 at a single institution. Weekly peer review rounds are grouped according to cancer subsite and attended by radiation oncologists, medical physicists and medical radiation technologists. We prospectively compiled ‘learning moments’, defined as cases with suggested changes or where an educational discussion occurred beyond routine management, and critical errors, defined as errors which could alter clinical outcomes, recorded prospectively during peer review. Plan changes implemented after peer review were documented.
Results:
Nine hundred thirty-four SBRT cases were included. The most common treatment sites were lung (518, 55%), liver (196, 21%) and spine (119, 13%). Learning moments were identified in 161 cases (17%) and translated into plan changes in 28 cases (3%). Two critical errors (0.2%) were identified: an inadequate planning target volume margin and an incorrect image set used for contouring. There was a statistically significantly higher rate of learning moments for lower-volume SBRT sites (defined as ≤30 cases/year) versus higher-volume SBRT sites (29% vs 16%, respectively; p = 0.001).
Conclusions:
Peer review for SBRT cases revealed a low rate of critical errors, but did result in implemented plan changes in 3% of cases, and either educational discussion or suggestions of plan changes in 17% of cases. All SBRT sites appear to benefit from peer review, though lower-volume sites may require particular attention.
The science-informed approach to clinical practice is founded upon ongoing quality improvement and involves key skills that allow clinical psychologists to confidently provide services in a competitive health care market. Thus, programme evaluation is a core clinical psychology competency but needs to be provided via a co-design framework. The chapter outlines how co-designed programme evaluation addresses patients’ needs in five steps: (i) asking the right questions, (ii) developing an evaluation plan, (iii) collecting and analysing data to produce usable findings, (iv) translating the findings into recommendations for action, and (v) advocating and promoting change. The chapter illustrates how empirically-based programme evaluation supports accountable clinical practice, both at the level of the individual patient and at the aggregate level of the service provider or agency.
Following an overview of Quality Management concepts and the creation of a Quality Management System (QMS) there is a discussion of the principles of Accreditation and Accreditation schemes. The importance of training is emphasized, and the goal-orientated reiterative assessments apporach described, including defining criteria for competence as the endpoint of training. There are also discussion on quality control, measurement uncertainty, test method selection and comparison,laboratory equipment monitoring, and External Quality Assurance (EQA). A section on regulatory aspects includes a comparison between Standards (including the new ISO 23162) and guidelines. A final section describes a framework for validating new test methods.
This paper focuses on quality assurance in language massive open online courses (LMOOCs). It is a qualitative study that adopts the grounded theory method and analyses evaluative comments on the quality of LMOOCs from learners’ perspectives. With the data collected from 1,000 evaluations from English as a second language (ESL) learners on China’s biggest MOOC platform “iCourse”, this study examines what has influenced learners’ perceptions of LMOOCs and identifies the specific quality criteria of five types of them, including ESL courses for speaking, reading, writing, cultural studies, and integrated skills. The results of the study will lay a foundation for the establishment of a quality criteria framework for LMOOCs and provide insights into design principles for effective online language courses tailored to the diverse needs of a massive number of language learners.
Here we consider various examples of legal and regulatory responses to avoidable adverse medication events. There are a wide range of poorly interlinked regulatory processes, regardless of the country examined. Some approaches are proactive while others are reactive, serving mostly to provide compensation or to punish those felt responsible. Regulation can assist in promoting medication safety through influence and through compulsion, but what is really required is the whole-hearted engagement of everyone in the organization in the mission of achieving safe, high quality patient care. This goal will require both physician efforts, through professionalism and self regulation, and those of hospital boards of directors, through setting priorities and driving a just culture. While there is a role for the civil law (compensation for injured and in some degree of declarative retribution), litigation is likely to most effective when it is directed against institutions. The best approaches are based on “full disclosure and rapid compensation” practices. Criminal action in the regulation of safe medication practices in the perioperative period should be reserved for when recklessness is involved or where deliberate malfeasance is a factor.
This chapter seeks to give an overview of the place of Quality Management (QM) in contemporary fertility practice. It provides the reader with an understanding of the terminology used in QM and explores the definition of quality and success in fertility care. An examination of process modelling in the organisation of services is outlined and an analysis in practical terms as to how QM is applied in practice is provided, covering key issues such as document control, organisational structure and the role of the quality manager. Audit as a tool for improving quality is a fundamental tool and its use within a clinical governance framework including risk management/assessment, and other key responsibilities is detailed. Measuring what we do, analysing performance and setting targets to improve should be fundamental to how we approach our work in contemporary clinical practice.